• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by vTv Therapeutics Inc.

    5/1/25 4:28:23 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTVT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001957337
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    vTv Therapeutics Inc.
    SEC File Number
    001-37524
    Address of Issuer
    3980 Premier Drive,
    Suite 310
    High Point
    NORTH CAROLINA
    27265
    Phone
    (336) 841-0300
    Name of Person for Whose Account the Securities are To Be Sold
    STEVEN TUCH
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    125825160.00319456405/01/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/15/2025Exercised SharesIssuerCheckbox not checked125804/15/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/29/2025100021500.00
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/24/2025100021500.00
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/22/2025100019000.20
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/10/20254007147.32
    STEVEN TUCH
    3980 Premier Drive,
    Suite 310
    High Point � NC � 27265
    Common04/10/20253005417.16

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/01/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Steven L. Tuch

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VTVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTVT

    DatePrice TargetRatingAnalyst
    2/18/2022$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $VTVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by vTv Therapeutics Inc.

      SC 13G - vTv Therapeutics Inc. (0001641489) (Subject)

      11/12/24 10:40:28 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by vTv Therapeutics Inc. (Amendment)

      SC 13D/A - vTv Therapeutics Inc. (0001641489) (Subject)

      3/22/24 4:57:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by vTv Therapeutics Inc.

      SC 13D - vTv Therapeutics Inc. (0001641489) (Subject)

      3/5/24 7:52:29 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Financials

    Live finance-specific insights

    See more
    • vTv Therapeutics Announces Investment by CinRx Pharma

      HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ("CinPax"), a subsidiary of CinRx Pharma, LLC ("CinRx"). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA ap

      7/25/22 7:00:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    SEC Filings

    See more
    • vTv Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - vTv Therapeutics Inc. (0001641489) (Filer)

      5/19/25 4:24:13 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - vTv Therapeutics Inc. (0001641489) (Filer)

      5/16/25 9:05:21 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - vTv Therapeutics Inc. (0001641489) (Filer)

      5/15/25 4:11:25 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres, CEO and Exec Chairperson Sekhri Paul J bought $83,812 worth of shares (5,000 units at $16.76) (SEC Form 4)

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      11/19/24 4:31:06 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

      HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, which recently reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of

      5/19/25 9:00:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

      Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2025, and provided an update on recent corporate developments. "Our late stage cadisegliatin program is advancing with potential to be the first oral adjunct t

      5/15/25 4:01:00 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

      Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has been reinitiated in the Company's CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D). Cadisegliatin is a potential first-in-class, oral, liver-selective glucokinase activator for T1D that has been granted Breakthrough Therapy designation by the Food an

      5/15/25 12:00:00 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on vTv Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of vTv Therapeutics with a rating of Overweight and set a new price target of $5.00

      2/18/22 6:42:27 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VTVT
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 4 filed by EVP & CFO Tung Michael Stephen

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      5/21/25 6:17:21 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Tung Michael Stephen

      3 - vTv Therapeutics Inc. (0001641489) (Issuer)

      5/21/25 6:16:07 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Akkaraju Srinivas

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      4/24/25 4:40:29 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

      HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, which recently reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of

      5/19/25 9:00:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

      Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate de

      3/20/25 5:35:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

      HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. "Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on a consulting basis for several months, is now leading our work on the cadisegliatin Phase 3 program with the goal of initiating studies as soon as possible," said Paul Sekhri, Chief Executive Offi

      11/9/23 4:30:00 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care